Why Moderna Stock Rose Today @themotleyfool #stocks $MRNA
Importantly, Moderna also said that 37% of study participants are minorities, which the company believes helps to represent the broad diversity of the U.S. population.
Over 25,000 participants have already received their second dose of the experimental vaccine. Moderna said it will decide whether to ask the Food and Drug Administration for emergency use authorization after it collects two months of safety data on roughly half of the study’s participants.
Moderna is competing with the likes of Pfizer, AstraZeneca, Johnson & Johnson, and a host of other organizations in the race to find a safe and effective COVID-19 vaccine. Being first to market would give the winner advantages in terms of initial sales and development funding, and investors understandably cheered Moderna’s potential progress in this regard.
Google News – Business – Latest